Interpace Diagnostics Launches New Streamlined Molecular Product for Pancreatic Cysts

LW Newsfeed
Interpace Diagnostics Group (NASDAQ: IDXG), a provider of molecular diagnostic tests and pathology services, has completed its initial launch of PanDNA®, a new product that stratifies patients’ risk of developing pancreatic cancer based on three specific molecular criteria.

PanDNA was developed using the Company’s proprietary database of results for over 15,000 patients with pancreatic cysts.

Annually, over 170,000 patients in the US are identified with pancreatic cysts via imaging studies and referred by Radiologists to a Gastroenterologist for further risk assessment. PanDNA is designed to aid in this assessment. Read more . . .


Conversation